Discovery Labs Inc (DSCO) 3.50 $DSCO Discovery
Post# of 273257
Posted On: 09/03/2016 7:07:10 PM
Discovery Labs Inc (DSCO) 3.50 $DSCO
Discovery Labs Changes Name to Windtree Therapeutics, Inc. (NASDAQ: WINT)
PR Newswire - Mon Apr 18, 7:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has changed its corporate name to Windtree Therapeutics, Inc. and will trade under the Nasdaq symbol "WINT" effective at market open on Tuesday, April 19, 2016.
DSCO: 3.50 (-0.36)
Top Stocks Investors Are Considering on Monday April 11th
ACCESSWIRE - Mon Apr 11, 11:16AM CDT
MIAMI, FL / ACCESSWIRE / April 11, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EGLE, COOL, DSCO, and CRBP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EGLE: 7.30 (+0.23), COOL: 3.70 (-0.05), CRBP: 4.27 (+0.07), DSCO: 3.50 (-0.36)
4 Growth Stocks to Buy Near Their 52-Week Lows
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:14AM CDT
Several investors chose to cash in at current valuations thereby triggering a sell-off and exerting downward pressure on many fundamentally attractive stocks.
NSPR: 0.14 (unch), DSCO: 3.50 (-0.36), VNR: 1.31 (+0.08), XOMA: 0.56 (unch)
Discovery Labs Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Feb 03, 3:06PM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that its Board of Directors has approved an inducement award as a component of employment compensation for Craig Fraser, its newly appointed President and Chief Executive Officer. The award was approved by the Board's Compensation Committee on February 1, 2016 and granted as an inducement material to Mr. Fraser's employment with Discovery Labs in accordance with NASDAQ Listing Rule 5635(c)(4). Discovery Labs announced in a press release on February 1, 2016 and reported in its Current Report on Form 8-K filed today with the Securities and Exchange Commission that Mr. Fraser was appointed President and Chief Executive Officer effective February 1, 2016. This award was made outside of the Company's 2011 Long-Term Incentive Plan ("2011 Plan"
, but will be subject to terms and conditions generally consistent with those in the 2011 Plan.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Appointment of New Chief Executive Officer and Provides an Update on AEROSURF® Phase 2 Program
PR Newswire - Mon Feb 01, 3:01PM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced the appointment of a new Chief Executive Officer and has provided an update on its AEROSURF phase 2 program.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Reverse Stock Split
PR Newswire - Thu Jan 21, 3:10PM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has filed a Certificate of Amendment ("Amendment" to its Amended and Restated Certificate of Incorporation, as previously amended ("Certificate of Incorporation" to effect a consolidation, or reverse stock split ("reverse split" , at a ratio of one share of newly issued common stock for each 14 shares of issued and outstanding common stock, effective at 12:01 a.m. on January 22, 2016 ("Effective Time" . The Amendment also reduces the number of shares of common stock authorized under the Certificate of Incorporation from 250 million to 36 million. Because the Amendment does not reduce the number of authorized shares of common stock in the same proportion as the reverse split, the Amendment will have the effect of increasing the amount of common stock available for issuance relative to the amount of Common Stock available for issuance prior to the Amendment.
DSCO: 3.50 (-0.36)
Discovery Laboratories Advances Respiratory Disease Drug
Zacks Equity Research - Zacks Investment Research - Wed Dec 30, 3:55PM CST
Discovery Laboratories, Inc. (DSCO) announced that it has initiated a phase IIb study.
ACHN: 8.12 (-0.11), HZNP: 17.84 (-0.78), TEVA: 51.22 (+0.32), DSCO: 3.50 (-0.36)
Discovery Labs Announces Initiation of AEROSURF® Phase 2b Clinical Trial
PR Newswire - Tue Dec 29, 3:05PM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated its AEROSURF® phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS). The trial is designed to evaluate premature infants receiving aerosolized KL4 surfactant (including potentially repeat doses) compared to nCPAP alone. Two dose groups will be evaluated. The primary objective of the trial is to demonstrate evidence of efficacy and, if successful, inform the design of a phase 3 clinical program.
DSCO: 3.50 (-0.36)
Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age Presented at the 2015 Hot Topics in Neonatology Annual Meeting
PR Newswire - Thu Dec 10, 6:30AM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that data from the AEROSURF® Phase 2a clinical program in premature infants 29 to 34 weeks gestational age (GA) with respiratory distress syndrome (RDS) were presented at the 2015 Hot Topics in Neonatology Annual Meeting held December 6 - 9 in Washington D.C. The presentation, titled "Aerosolized Surfactant - Safety and Tolerability of Lucinactant for Inhalation in Preterm Infants", was made by Neil Finer, M.D, Professor Emeritus, Division of Neonatology, University of California, San Diego, and Chairman of the AEROSURF Steering Committee. Discovery Labs had previously released top-line results of the AEROSURF Phase 2a clinical program in premature infants 29 to 34 weeks GA in November 2015.
DSCO: 3.50 (-0.36)
Discovery Labs to Announce Results from AEROSURF® Phase 2a Expansion Clinical Trial
PR Newswire - Fri Nov 06, 7:30AM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will announce top-line results from its AEROSURF® Phase 2a expansion clinical trial in premature infants 29 - 34 gestational age with respiratory distress syndrome (RDS) on Thursday, November 12, 2015 at approximately 7:00 a.m. EST.
DSCO: 3.50 (-0.36)
Discovery Labs Provides Business Update and Reports Third Quarter 2015 Financial Results
PR Newswire - Thu Nov 05, 3:15PM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today provided a business update and financial results for the third quarter ended September 30, 2015.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Completion of Enrollment in AEROSURF® Phase 2a Dose Expansion Trial
PR Newswire - Wed Oct 21, 6:30AM CDT
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed enrollment in the AEROSURF® phase 2a dose expansion clinical trial to assess the administration of higher doses of AEROSURF in premature infants 29 to 34 week gestational age (GA) with respiratory distress syndrome (RDS). With the completion of enrollment in this trial, the Company expects to initiate its AEROSURF phase 2b trial in the fourth quarter of 2015 beginning with premature infants 29 to 32 weeks GA.
DSCO: 3.50 (-0.36)
Hot Stock: Discovery Laboratories, Shares Drop 8.8% (DSCO)
Comtex SmarTrend(R) - Mon Sep 28, 11:59AM CDT
Discovery Laboratories (NASDAQ
SCO) is one of today's worst performing penny stocks, down 8.8% to $0.31 on 1.3x average daily volume. Discovery Laboratories has traded 427,000 shares thus far today, vs. average volume of 341,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's -1.5%) and underperformed the S&P 500 (-8.8% to the S&P's -1.9%) during today's trading.
DSCO: 3.50 (-0.36)
Market Pulse of the Healthcare Sector - Anthera Pharmaceuticals, Flexion Therapeutics, AcelRx Pharmaceuticals, Discovery Laboratories and Cara Therapeutics
PR Newswire - Mon Sep 28, 8:12AM CDT
ACI Association has initiated research coverage on the following equities: Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), Flexion Therapeutics, Inc. (NASDAQ: FLXN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Discovery Laboratories, Inc. (NASDAQ: DSCO), and Cara Therapeutics, Inc. (NASDAQ: CARA). On Friday, September 25, 2015, Nasdaq ended at 4,686.50, down 1.01%, Dow Jones advanced 0.70% to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
ACRX: 3.09 (+0.04), CARA: 5.32 (-0.06), FLXN: 16.83 (-0.08), ANTH: 2.93 (+0.02), DSCO: 3.50 (-0.36)
Discovery Labs Provides Business Update and Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 3:45PM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today provided a corporate update, and announced financial results for the second quarter ended June 30, 2015. The Company will host a conference call Tuesday August 11, 2015 at 8:30 AM ET. Conference call details are below.
DSCO: 3.50 (-0.36)
Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates
PR Newswire - Mon Aug 03, 3:15PM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a live teleconference and webcast at 8:30 a.m. Eastern Time on Tuesday August 11, 2015 at which time management will discuss the 2015 second quarter financial results along with providing other business updates. The company will issue a press release announcing the second quarter 2015 financial results after the close of the U.S. financial markets on Monday, August 10, 2015.
DSCO: 3.50 (-0.36)
Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury
PR Newswire - Thu Jul 30, 6:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has received the second $1.0M tranche under a previously awarded Phase II Small Business Innovation Research (SBIR) grant valued at up to $3.0 million to support continued development of the company's aerosolized KL4 surfactant as a potential medical countermeasure to mitigate acute and chronic/late-phase radiation-induced lung injury. Discovery Labs was awarded an initial $1.0 million under this grant in October 2014 and over the next year may be awarded up to an additional $1.0 million following completion of certain research activities.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Completion of $40.25 Million Public Offering
PR Newswire - Wed Jul 22, 3:15PM CDT
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering of 16.3 million Series A units and 42.0 million Series B units, at a public offering price of $0.60 per unit. In addition, on July 21, 2015, the underwriters notified the Company of their intention to exercise their option to purchase an additional 8.75 million Series A units to cover over-allotments, bringing the aggregate number of Series A units sold to 25.08 million. Each Series A unit consists of one share of common stock and a Series A warrant to purchase one share of common stock. Investors whose purchase of units in the offering would result in their beneficially owning more than the beneficial ownership limitation set forth in the warrants have had the opportunity to acquire, in lieu of Series A units, Series B units, each of which consists of one Pre-Funded Series B warrant to purchase one share of common stock at an initial exercise price of $0.60 per share, of which the entire amount has been pre-paid upon issuance, and one Series B warrant to purchase one share of common stock. The Series A and Series B warrants are exercisable immediately at an exercise price of $0.70 per share. All warrants will expire on the seventh anniversary of the issue date. The shares of common stock and warrants were immediately separable such that no units were issued.
DSCO: 3.50 (-0.36)
Technical Coverage on Biotechnology Equities -- Achillion Pharma, CTI BioPharma, Enzon Pharma, Discovery Laboratories, and Pacific Biosciences of California
PR Newswire - Mon Jul 20, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Discovery Laboratories Inc. (NASDAQ: DSCO), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Free research report on Achillion Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ACHN On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PACB: 8.28 (-0.02), ACHN: 8.12 (-0.11), CTIC: 0.39 (unch), DSCO: 3.50 (-0.36)
Discovery Labs Changes Name to Windtree Therapeutics, Inc. (NASDAQ: WINT)
PR Newswire - Mon Apr 18, 7:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has changed its corporate name to Windtree Therapeutics, Inc. and will trade under the Nasdaq symbol "WINT" effective at market open on Tuesday, April 19, 2016.
DSCO: 3.50 (-0.36)
Top Stocks Investors Are Considering on Monday April 11th
ACCESSWIRE - Mon Apr 11, 11:16AM CDT
MIAMI, FL / ACCESSWIRE / April 11, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EGLE, COOL, DSCO, and CRBP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EGLE: 7.30 (+0.23), COOL: 3.70 (-0.05), CRBP: 4.27 (+0.07), DSCO: 3.50 (-0.36)
4 Growth Stocks to Buy Near Their 52-Week Lows
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:14AM CDT
Several investors chose to cash in at current valuations thereby triggering a sell-off and exerting downward pressure on many fundamentally attractive stocks.
NSPR: 0.14 (unch), DSCO: 3.50 (-0.36), VNR: 1.31 (+0.08), XOMA: 0.56 (unch)
Discovery Labs Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Feb 03, 3:06PM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that its Board of Directors has approved an inducement award as a component of employment compensation for Craig Fraser, its newly appointed President and Chief Executive Officer. The award was approved by the Board's Compensation Committee on February 1, 2016 and granted as an inducement material to Mr. Fraser's employment with Discovery Labs in accordance with NASDAQ Listing Rule 5635(c)(4). Discovery Labs announced in a press release on February 1, 2016 and reported in its Current Report on Form 8-K filed today with the Securities and Exchange Commission that Mr. Fraser was appointed President and Chief Executive Officer effective February 1, 2016. This award was made outside of the Company's 2011 Long-Term Incentive Plan ("2011 Plan"
, but will be subject to terms and conditions generally consistent with those in the 2011 Plan. DSCO: 3.50 (-0.36)
Discovery Labs Announces Appointment of New Chief Executive Officer and Provides an Update on AEROSURF® Phase 2 Program
PR Newswire - Mon Feb 01, 3:01PM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced the appointment of a new Chief Executive Officer and has provided an update on its AEROSURF phase 2 program.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Reverse Stock Split
PR Newswire - Thu Jan 21, 3:10PM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has filed a Certificate of Amendment ("Amendment"
to its Amended and Restated Certificate of Incorporation, as previously amended ("Certificate of Incorporation" to effect a consolidation, or reverse stock split ("reverse split" , at a ratio of one share of newly issued common stock for each 14 shares of issued and outstanding common stock, effective at 12:01 a.m. on January 22, 2016 ("Effective Time" . The Amendment also reduces the number of shares of common stock authorized under the Certificate of Incorporation from 250 million to 36 million. Because the Amendment does not reduce the number of authorized shares of common stock in the same proportion as the reverse split, the Amendment will have the effect of increasing the amount of common stock available for issuance relative to the amount of Common Stock available for issuance prior to the Amendment. DSCO: 3.50 (-0.36)
Discovery Laboratories Advances Respiratory Disease Drug
Zacks Equity Research - Zacks Investment Research - Wed Dec 30, 3:55PM CST
Discovery Laboratories, Inc. (DSCO) announced that it has initiated a phase IIb study.
ACHN: 8.12 (-0.11), HZNP: 17.84 (-0.78), TEVA: 51.22 (+0.32), DSCO: 3.50 (-0.36)
Discovery Labs Announces Initiation of AEROSURF® Phase 2b Clinical Trial
PR Newswire - Tue Dec 29, 3:05PM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated its AEROSURF® phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS). The trial is designed to evaluate premature infants receiving aerosolized KL4 surfactant (including potentially repeat doses) compared to nCPAP alone. Two dose groups will be evaluated. The primary objective of the trial is to demonstrate evidence of efficacy and, if successful, inform the design of a phase 3 clinical program.
DSCO: 3.50 (-0.36)
Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age Presented at the 2015 Hot Topics in Neonatology Annual Meeting
PR Newswire - Thu Dec 10, 6:30AM CST
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that data from the AEROSURF® Phase 2a clinical program in premature infants 29 to 34 weeks gestational age (GA) with respiratory distress syndrome (RDS) were presented at the 2015 Hot Topics in Neonatology Annual Meeting held December 6 - 9 in Washington D.C. The presentation, titled "Aerosolized Surfactant - Safety and Tolerability of Lucinactant for Inhalation in Preterm Infants", was made by Neil Finer, M.D, Professor Emeritus, Division of Neonatology, University of California, San Diego, and Chairman of the AEROSURF Steering Committee. Discovery Labs had previously released top-line results of the AEROSURF Phase 2a clinical program in premature infants 29 to 34 weeks GA in November 2015.
DSCO: 3.50 (-0.36)
Discovery Labs to Announce Results from AEROSURF® Phase 2a Expansion Clinical Trial
PR Newswire - Fri Nov 06, 7:30AM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will announce top-line results from its AEROSURF® Phase 2a expansion clinical trial in premature infants 29 - 34 gestational age with respiratory distress syndrome (RDS) on Thursday, November 12, 2015 at approximately 7:00 a.m. EST.
DSCO: 3.50 (-0.36)
Discovery Labs Provides Business Update and Reports Third Quarter 2015 Financial Results
PR Newswire - Thu Nov 05, 3:15PM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today provided a business update and financial results for the third quarter ended September 30, 2015.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Completion of Enrollment in AEROSURF® Phase 2a Dose Expansion Trial
PR Newswire - Wed Oct 21, 6:30AM CDT
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed enrollment in the AEROSURF® phase 2a dose expansion clinical trial to assess the administration of higher doses of AEROSURF in premature infants 29 to 34 week gestational age (GA) with respiratory distress syndrome (RDS). With the completion of enrollment in this trial, the Company expects to initiate its AEROSURF phase 2b trial in the fourth quarter of 2015 beginning with premature infants 29 to 32 weeks GA.
DSCO: 3.50 (-0.36)
Hot Stock: Discovery Laboratories, Shares Drop 8.8% (DSCO)
Comtex SmarTrend(R) - Mon Sep 28, 11:59AM CDT
Discovery Laboratories (NASDAQ
SCO) is one of today's worst performing penny stocks, down 8.8% to $0.31 on 1.3x average daily volume. Discovery Laboratories has traded 427,000 shares thus far today, vs. average volume of 341,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's -1.5%) and underperformed the S&P 500 (-8.8% to the S&P's -1.9%) during today's trading. DSCO: 3.50 (-0.36)
Market Pulse of the Healthcare Sector - Anthera Pharmaceuticals, Flexion Therapeutics, AcelRx Pharmaceuticals, Discovery Laboratories and Cara Therapeutics
PR Newswire - Mon Sep 28, 8:12AM CDT
ACI Association has initiated research coverage on the following equities: Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), Flexion Therapeutics, Inc. (NASDAQ: FLXN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Discovery Laboratories, Inc. (NASDAQ: DSCO), and Cara Therapeutics, Inc. (NASDAQ: CARA). On Friday, September 25, 2015, Nasdaq ended at 4,686.50, down 1.01%, Dow Jones advanced 0.70% to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
ACRX: 3.09 (+0.04), CARA: 5.32 (-0.06), FLXN: 16.83 (-0.08), ANTH: 2.93 (+0.02), DSCO: 3.50 (-0.36)
Discovery Labs Provides Business Update and Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 3:45PM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today provided a corporate update, and announced financial results for the second quarter ended June 30, 2015. The Company will host a conference call Tuesday August 11, 2015 at 8:30 AM ET. Conference call details are below.
DSCO: 3.50 (-0.36)
Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates
PR Newswire - Mon Aug 03, 3:15PM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a live teleconference and webcast at 8:30 a.m. Eastern Time on Tuesday August 11, 2015 at which time management will discuss the 2015 second quarter financial results along with providing other business updates. The company will issue a press release announcing the second quarter 2015 financial results after the close of the U.S. financial markets on Monday, August 10, 2015.
DSCO: 3.50 (-0.36)
Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury
PR Newswire - Thu Jul 30, 6:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has received the second $1.0M tranche under a previously awarded Phase II Small Business Innovation Research (SBIR) grant valued at up to $3.0 million to support continued development of the company's aerosolized KL4 surfactant as a potential medical countermeasure to mitigate acute and chronic/late-phase radiation-induced lung injury. Discovery Labs was awarded an initial $1.0 million under this grant in October 2014 and over the next year may be awarded up to an additional $1.0 million following completion of certain research activities.
DSCO: 3.50 (-0.36)
Discovery Labs Announces Completion of $40.25 Million Public Offering
PR Newswire - Wed Jul 22, 3:15PM CDT
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering of 16.3 million Series A units and 42.0 million Series B units, at a public offering price of $0.60 per unit. In addition, on July 21, 2015, the underwriters notified the Company of their intention to exercise their option to purchase an additional 8.75 million Series A units to cover over-allotments, bringing the aggregate number of Series A units sold to 25.08 million. Each Series A unit consists of one share of common stock and a Series A warrant to purchase one share of common stock. Investors whose purchase of units in the offering would result in their beneficially owning more than the beneficial ownership limitation set forth in the warrants have had the opportunity to acquire, in lieu of Series A units, Series B units, each of which consists of one Pre-Funded Series B warrant to purchase one share of common stock at an initial exercise price of $0.60 per share, of which the entire amount has been pre-paid upon issuance, and one Series B warrant to purchase one share of common stock. The Series A and Series B warrants are exercisable immediately at an exercise price of $0.70 per share. All warrants will expire on the seventh anniversary of the issue date. The shares of common stock and warrants were immediately separable such that no units were issued.
DSCO: 3.50 (-0.36)
Technical Coverage on Biotechnology Equities -- Achillion Pharma, CTI BioPharma, Enzon Pharma, Discovery Laboratories, and Pacific Biosciences of California
PR Newswire - Mon Jul 20, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Discovery Laboratories Inc. (NASDAQ: DSCO), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Free research report on Achillion Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ACHN On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PACB: 8.28 (-0.02), ACHN: 8.12 (-0.11), CTIC: 0.39 (unch), DSCO: 3.50 (-0.36)
(0)
(0)Scroll down for more posts ▼